



D A N B I O

DANSK REUMATOLOGISK DATABASE

DANBIO - 15 år - seminar

Fredag den 9. september 2016

Hotel Park Inn by Radisson, Engvej 171, 2300 København S
(tæt på metrostationen Femøren)

Vi har den store glæde at invitere alle interessererede til en begivenhedsrig dag med foredragsholdere fra ind- og udland. Arrangementet er tværfagligt. Formiddagen giver en opdatering på smerteforskning og eftermiddagen byder på highlights fra den seneste forskning, som er publiceret på baggrund af bl.a. DANBIO data.

PROGRAM

09.30 - 10.00 **Coffee/breakfast**

10.00 - 10.30 **Introduction**

Medical Director Per Jørgensen, MD, DMSc, MPM, Rigshospitalet

DANBIO - Perspectives at 15 years

Professor, Merete Lund Hetland, MD, PhD, DMSc, Head of DANBIO's steering committee, COPECARE, VRR, Rigshospitalet, Glostrup

PAIN IN ARTHRITIS – CAN WE DO BETTER?

10.30 **Is the disease burden in osteoarthritis as great as in rheumatoid arthritis? Lessons from the MDHAQ in routine care**
Ted Pincus, MD, Rush University Medical Center, Chicago, Illinois, USA

Chronic pain in the general population – The DanFunD study

Professor Torben Jørgensen, MD, DMSc, Research Centre for Prevention and Health, Centre of Health, Capital Region

Coffee break

The role of sensitisation in patients with joint pain: Implications for diagnosis and treatment

Professor Lars Arendt-Nielsen, dr.med.sci., Center for Sensory-Motor Interaction, Aalborg University


Persistent pain and possible pain mechanisms in patients with inflammatory arthritis

Signe Rifbjerg-Madsen, MD, PhD-student, Parker Institute, Frederiksberg Hospital

13.00 **Lunch**

14.00 **The DANBIO registry from a patient's perspective**

The Danish Rheumatism Association, Project Manager Connie Ziegler



HIGHLIGHTS FROM ONGOING RESEARCH INVOLVING DANBIO

14.10

Clinical remission in RA on biologics - should we reduce the dose?

Cecilie Heegaard, MD, PhD-student, COPECARE, VRR, Rigshospitalet, Glostrup

Non-medical switch to biosimilars infliximab in routine care, results from DANBIO and the Danish Rheumatologic Biobank

Bente Glintborg, Consultant, PhD, COPECARE, VRR, Gentofte Hospital and Rigshospitalet, Glostrup

Obesity impairs the response to tumour necrosis factor-alpha inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries

Pil Højgaard, MD, PhD-student, COPECARE, VRR, Gentofte Hospital og Parker Institute, Frederiksberg Hospital

RA and work: Risk and risk factors for long term sickness absence, unemployment, and disability pension

Sofie Mandrup Hansen, Cand.Scient., PhD, National Research Center for the Working Environment, Capital Region and COPECARE, VRR, Rigshospitalet, Glostrup

The risk of infections in RA patient treated with biologic DMARDs

Mai Nguyen, MD, PhD-student, Infektionsmedicinsk afd., Odense Universitets Hospital

15.00 - 15.30

Coffee break

15.30

The linear HAQ score? Analyses of Patient Reported Outcomes from DANBIO.

Lykke Midtbøl Ørnbjerg, MD, PhD, COPECARE, VRR, Rigshospitalet, Glostrup

The Imagine study

Signe Møller Bisgaard, MD, PhD, COPECARE, VRR, Rigshospitalet, Glostrup and Slagelse Hospital

Medical treatment of rheumatoid arthritis and risk of complications following total joint arthroplasty

René Cordtz, MD, PhD-student, COPECARE, VRR, Gentofte Hospital and Parker Institute, Frederiksberg Hospital

Screening and management of cardiovascular risk in patients with inflammatory arthritis using DANBIO as a tool - what have we learned?

Jette Primdahl, Research nurse, PhD, Kong Christian X's Gighospital, Gråsten

Risk of neurologic side effects in arthritis patients treated with biologics

Lene Dreyer, Consultant, PhD, COPECARE, VRR, Gentofte Hospital and Parker Institute, Frederiksberg Hospital and PROCRIN.

What's in the pipeline?

Professor Merete Lund Hetland, MD, PhD, DMSc Head of DANBIO's steering committee, COPECARE, VRR, Rigshospitalet, Glostrup.

16.45

Summary and conclusion

Tilmelding senest den 18. August 2016 til databasen@danbio-online.dk